ARGX vs. GKOS: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ARGX and GKOS, comparing key factors like performance, valuation metrics, dividends, and financial strength.
Company Overview
ARGX’s market capitalization of 35.78 billion USD is substantially larger than GKOS’s 5.40 billion USD, indicating a significant difference in their market valuations.
GKOS carries a higher beta at 0.81, indicating it’s more sensitive to market moves, while ARGX (beta: 0.04) exhibits greater stability.
ARGX trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, GKOS is a standard domestic listing.
Symbol | ARGX | GKOS |
---|---|---|
Company Name | argenx SE | Glaukos Corporation |
Country | NL | US |
Sector | Healthcare | Healthcare |
Industry | Biotechnology | Medical - Devices |
CEO | Mr. Timothy Van Hauwermeiren EMBA, M.Sc. | Mr. Thomas William Burns |
Price | 585.93 USD | 94.475 USD |
Market Cap | 35.78 billion USD | 5.40 billion USD |
Beta | 0.04 | 0.81 |
Exchange | NASDAQ | NYSE |
IPO Date | May 18, 2017 | June 25, 2015 |
ADR | Yes | No |
Performance Comparison
This chart compares the performance of ARGX and GKOS over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
This section compares the market valuation of ARGX and GKOS. Key takeaways regarding their valuation, when viewed within their industry context, are presented in the commentary that follows.
- GKOS’s Price-to-Earnings (P/E) ratio of -43.26 is negative. This indicates the company is currently not generating profit, a key factor that can weigh on its stock valuation and investor sentiment.
- GKOS’s Forward PEG ratio of -2.43 is negative. Such a figure commonly arises from negative earnings or forecasts of diminishing profitability, making standard valuation comparisons based on growth particularly challenging.
- GKOS’s Price-to-Book (P/B) ratio of 7.00 is very high. This suggests that investors are valuing its assets and growth potential at a considerable premium to its stated book value, often due to strong return on equity, significant intangible assets, or optimistic growth forecasts.
Symbol | ARGX | GKOS |
---|---|---|
Price-to-Earnings Ratio (P/E, TTM) | 51.86 | -43.26 |
Forward PEG Ratio (TTM) | 1.35 | -2.43 |
Price-to-Sales Ratio (P/S, TTM) | 16.75 | 13.34 |
Price-to-Book Ratio (P/B, TTM) | 7.87 | 7.00 |
EV-to-EBITDA (TTM) | 4645.24 | -67.09 |
EV-to-Sales (TTM) | 16.09 | 13.32 |
Dividend Comparison
Neither ARGX nor GKOS currently pays a dividend; this often suggests they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
Symbol | ARGX | GKOS |
---|---|---|
Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section evaluates the financial strength of ARGX and GKOS. Noteworthy observations on their financial resilience, considered from an industry perspective, are detailed in the points that follow.
- ARGX’s Interest Coverage Ratio (ICR) of -20.85 and GKOS’s ICR of -13.09 are both negative. For ARGX, a negative ICR means its operating earnings are insufficient to cover its interest expenses, a critical indicator of financial distress. GKOS’s negative ICR likewise signals severe difficulty in servicing its debt and raises concerns about its ongoing financial stability.
Symbol | ARGX | GKOS |
---|---|---|
Current Ratio (TTM) | 7.29 | 6.49 |
Quick Ratio (TTM) | 6.68 | 5.62 |
Debt-to-Equity Ratio (TTM) | 0.01 | 0.14 |
Debt-to-Asset Ratio (TTM) | 0.01 | 0.11 |
Net Debt-to-EBITDA Ratio (TTM) | -189.75 | 0.11 |
Interest Coverage Ratio (TTM) | -20.85 | -13.09 |